|
US7772432B2
(en)
*
|
1991-09-19 |
2010-08-10 |
Astrazeneca Ab |
Amidobenzamide derivatives which are useful as cytokine inhibitors
|
|
US6811779B2
(en)
|
1994-02-10 |
2004-11-02 |
Imclone Systems Incorporated |
Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
|
|
US7060808B1
(en)
*
|
1995-06-07 |
2006-06-13 |
Imclone Systems Incorporated |
Humanized anti-EGF receptor monoclonal antibody
|
|
BR9707495A
(pt)
|
1996-02-13 |
1999-07-27 |
Zeneca Ltd |
Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
|
|
GB9603095D0
(en)
*
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
|
US6291455B1
(en)
|
1996-03-05 |
2001-09-18 |
Zeneca Limited |
4-anilinoquinazoline derivatives
|
|
HU228446B1
(en)
|
1996-04-12 |
2013-03-28 |
Warner Lambert Co |
Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof
|
|
GB9707800D0
(en)
|
1996-05-06 |
1997-06-04 |
Zeneca Ltd |
Chemical compounds
|
|
ID19609A
(id)
|
1996-07-13 |
1998-07-23 |
Glaxo Group Ltd |
Senyawa-senyawa heterosiklik
|
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
|
US6225318B1
(en)
|
1996-10-17 |
2001-05-01 |
Pfizer Inc |
4-aminoquinazolone derivatives
|
|
AR012634A1
(es)
*
|
1997-05-02 |
2000-11-08 |
Sugen Inc |
Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
|
|
WO1999010349A1
(en)
|
1997-08-22 |
1999-03-04 |
Zeneca Limited |
Oxindolylquinazoline derivatives as angiogenesis inhibitors
|
|
GB9800575D0
(en)
*
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
|
RS49779B
(sr)
|
1998-01-12 |
2008-06-05 |
Glaxo Group Limited, |
Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
|
|
US20030224001A1
(en)
*
|
1998-03-19 |
2003-12-04 |
Goldstein Neil I. |
Antibody and antibody fragments for inhibiting the growth of tumors
|
|
ZA200007412B
(en)
*
|
1998-05-15 |
2002-03-12 |
Imclone Systems Inc |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
|
|
ATE232205T1
(de)
|
1998-10-01 |
2003-02-15 |
Astrazeneca Ab |
Chinolin- und chinazolin derivate und ihre verwendung als inhibitoren von krankheiten, bei denen cytokine beteiligt wird
|
|
UA71945C2
(en)
*
|
1999-01-27 |
2005-01-17 |
Pfizer Prod Inc |
Substituted bicyclic derivatives being used as anticancer agents
|
|
JP3270834B2
(ja)
*
|
1999-01-27 |
2002-04-02 |
ファイザー・プロダクツ・インク |
抗がん剤として有用なヘテロ芳香族二環式誘導体
|
|
SK288365B6
(sk)
*
|
1999-02-10 |
2016-07-01 |
Astrazeneca Ab |
Medziprodukty pre chinazolínové deriváty ako inhibítory angiogenézy
|
|
HK1047236A1
(zh)
*
|
1999-05-14 |
2003-02-14 |
Imclone Llc |
用表皮生长因子受体拮抗剂治疗难治的人肿瘤
|
|
EE04748B1
(et)
*
|
1999-06-21 |
2006-12-15 |
Boehringer Ingelheim Pharma Kg |
Bitsüklilised heterotsüklilised ühendid, neid ühendeid sisaldavad ravimid, nende kasutamine ja meetodid nende valmistamiseks
|
|
ATE377597T1
(de)
|
1999-07-09 |
2007-11-15 |
Glaxo Group Ltd |
Anilinochinazoline als protein-tyrosin- kinasehemmer
|
|
US6933299B1
(en)
|
1999-07-09 |
2005-08-23 |
Smithkline Beecham Corporation |
Anilinoquinazolines as protein tyrosine kinase inhibitors
|
|
KR20020032608A
(ko)
*
|
1999-09-21 |
2002-05-03 |
다비드 에 질레스 |
퀴나졸린 화합물 및 이를 함유하는 제약 조성물
|
|
CZ301689B6
(cs)
|
1999-11-05 |
2010-05-26 |
Astrazeneca Ab |
Derivát chinazolinu a farmaceutický prostredek, který ho obsahuje
|
|
UA75055C2
(uk)
*
|
1999-11-30 |
2006-03-15 |
Пфайзер Продактс Інк. |
Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
|
|
US6521618B2
(en)
|
2000-03-28 |
2003-02-18 |
Wyeth |
3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
|
|
ES2267748T3
(es)
|
2000-04-07 |
2007-03-16 |
Astrazeneca Ab |
Compuestos de quinazolina.
|
|
US6627634B2
(en)
*
|
2000-04-08 |
2003-09-30 |
Boehringer Ingelheim Pharma Kg |
Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
|
|
UA73993C2
(uk)
|
2000-06-06 |
2005-10-17 |
Астразенека Аб |
Хіназолінові похідні для лікування пухлин та фармацевтична композиція
|
|
HRP20021005A2
(en)
*
|
2000-06-22 |
2004-02-29 |
Pfizer Prod Inc |
Substituted bicyclic derivatives for the treatment of abnormal cell growth
|
|
AU9500201A
(en)
*
|
2000-08-09 |
2002-02-18 |
Imclone Systems Inc |
Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
|
|
CA2419301C
(en)
|
2000-08-21 |
2009-12-08 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
DE10042058A1
(de)
*
|
2000-08-26 |
2002-03-07 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
|
WO2002030926A1
(en)
|
2000-10-13 |
2002-04-18 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
US6849625B2
(en)
|
2000-10-13 |
2005-02-01 |
Astrazeneca Ab |
Quinazoline derivatives with anti-tumour activity
|
|
US7019012B2
(en)
*
|
2000-12-20 |
2006-03-28 |
Boehringer Ingelheim International Pharma Gmbh & Co. Kg |
Quinazoline derivatives and pharmaceutical compositions containing them
|
|
PL409579A1
(pl)
|
2001-02-19 |
2015-03-02 |
Novartis Ag |
Leczenie raka
|
|
US20080008704A1
(en)
*
|
2001-03-16 |
2008-01-10 |
Mark Rubin |
Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
|
|
PT1392313E
(pt)
|
2001-05-16 |
2007-07-17 |
Novartis Ag |
Combinação que compreende n - ( 5- [ 4- ( metil-piperazinomrtil ) - benxoilamido ] - 2 -metilfenil ) - 4 -( 3 - piridil ) - 2 - pirimidina-amina e um agente quimioterapêutico
|
|
JP2005515176A
(ja)
*
|
2001-11-03 |
2005-05-26 |
アストラゼネカ アクチボラグ |
抗腫瘍剤としてのキナゾリン誘導体
|
|
GB0126433D0
(en)
*
|
2001-11-03 |
2002-01-02 |
Astrazeneca Ab |
Compounds
|
|
CN1753903B
(zh)
*
|
2001-11-19 |
2010-05-12 |
白介素遗传公司 |
影响转录和对炎性和传染性疾病的敏感性的白细胞介素-1基因座的功能多态性
|
|
HUP0500117A3
(en)
*
|
2001-11-30 |
2008-03-28 |
Pfizer Prod Inc |
Processes for the preparation of substituted quinazoline derivatives for the treatment of abnormal cell growth
|
|
PL373848A1
(en)
*
|
2001-12-12 |
2005-09-19 |
Pfizer Products Inc. |
Quinazoline derivatives for the treatment of abnormal cell growth
|
|
GEP20063872B
(en)
*
|
2001-12-12 |
2006-07-10 |
Pfizer Prod Inc |
Salt forms of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quina-zolin-6-yl}-allyl)-acetamide and method of production
|
|
WO2003053958A1
(en)
*
|
2001-12-20 |
2003-07-03 |
Celltech R & D Limited |
Quinazolinedione derivatives
|
|
CN1627944A
(zh)
*
|
2002-01-17 |
2005-06-15 |
神经能质公司 |
取代的喹唑啉－4－基胺类似物作为辣椒辣素调节剂
|
|
JP4608215B2
(ja)
|
2002-02-01 |
2011-01-12 |
アストラゼネカ アクチボラグ |
キナゾリン化合物
|
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
|
TWI324597B
(en)
*
|
2002-03-28 |
2010-05-11 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
US6924285B2
(en)
*
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
|
CA2476008C
(en)
*
|
2002-03-30 |
2011-12-13 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
|
DE10221018A1
(de)
*
|
2002-05-11 |
2003-11-27 |
Boehringer Ingelheim Pharma |
Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
|
|
PL372103A1
(en)
|
2002-05-16 |
2005-07-11 |
Novartis Ag |
Use of edg receptor binding agents in cancer
|
|
EP2280003B1
(en)
|
2002-07-15 |
2014-04-02 |
Symphony Evolution, Inc. |
Process for preparing receptor-type kinase modulators
|
|
KR20050043923A
(ko)
*
|
2002-09-16 |
2005-05-11 |
알콘 매뉴팩츄어링, 리미티드 |
혈관신생 치료를 위한 ｐｄｅ-ⅳ 저해제의 용도
|
|
RU2350618C2
(ru)
*
|
2002-11-04 |
2009-03-27 |
Астразенека Аб |
ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ
|
|
CA2509233A1
(en)
*
|
2002-12-13 |
2004-07-01 |
Neurogen Corporation |
2-substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators
|
|
OA13309A
(en)
|
2002-12-20 |
2007-04-13 |
Pfizer Prod Inc |
Pyrimidine derivatives for the treatment of abnormal cell growth.
|
|
US7223749B2
(en)
*
|
2003-02-20 |
2007-05-29 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
|
|
EP1622941A2
(en)
*
|
2003-03-20 |
2006-02-08 |
ImClone Systems Incorporated |
Method of producing an antibody to epidermal growth factor receptor
|
|
WO2004092144A2
(en)
*
|
2003-04-16 |
2004-10-28 |
F. Hoffmann-La Roche Ag |
Quinazoline compounds useful as p38 kinase inhibitors
|
|
GB0309009D0
(en)
*
|
2003-04-22 |
2003-05-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
US7429603B2
(en)
*
|
2003-04-25 |
2008-09-30 |
3-Dimensional Pharmaceuticals, Inc. |
C-fms kinase inhibitors
|
|
GB0309850D0
(en)
|
2003-04-30 |
2003-06-04 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
BRPI0410439A
(pt)
|
2003-05-19 |
2006-06-06 |
Irm Llc |
compostos e composições imunossupressoras
|
|
MY150088A
(en)
|
2003-05-19 |
2013-11-29 |
Irm Llc |
Immunosuppressant compounds and compositions
|
|
JP4724657B2
(ja)
|
2003-05-30 |
2011-07-13 |
アストラゼネカ ユーケー リミテッド |
プロセス
|
|
CN1972712A
(zh)
|
2003-06-09 |
2007-05-30 |
塞缪尔·瓦克萨尔 |
用胞外拮抗物和胞内拮抗物抑制受体酪氨酸激酶的方法
|
|
US7329664B2
(en)
*
|
2003-07-16 |
2008-02-12 |
Neurogen Corporation |
Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
|
|
JP2007500177A
(ja)
*
|
2003-07-29 |
2007-01-11 |
アストラゼネカ アクチボラグ |
チロシンキナーゼ阻害剤としてのピペリジルキナゾリン誘導体
|
|
GB0317665D0
(en)
|
2003-07-29 |
2003-09-03 |
Astrazeneca Ab |
Qinazoline derivatives
|
|
US7501427B2
(en)
|
2003-08-14 |
2009-03-10 |
Array Biopharma, Inc. |
Quinazoline analogs as receptor tyrosine kinase inhibitors
|
|
WO2005016346A1
(en)
|
2003-08-14 |
2005-02-24 |
Array Biopharma Inc. |
Quinazoline analogs as receptor tyrosine kinase inhibitors
|
|
JP2007520444A
(ja)
*
|
2003-09-09 |
2007-07-26 |
ニューロジェン・コーポレーション |
置換二環式キナゾリン−４−イルアミン誘導体
|
|
AU2004272345A1
(en)
*
|
2003-09-16 |
2005-03-24 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
US20070032508A1
(en)
*
|
2003-09-16 |
2007-02-08 |
Bradbury Robert H |
Quinazoline derivatives as tyrosine kinase inhibitors
|
|
ES2305844T3
(es)
|
2003-09-16 |
2008-11-01 |
Astrazeneca Ab |
Derivados de quinazolina como inhibidores de tirosina cinasa.
|
|
WO2005028469A1
(en)
*
|
2003-09-19 |
2005-03-31 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
CN1882570B
(zh)
*
|
2003-09-19 |
2010-12-08 |
阿斯利康(瑞典)有限公司 |
喹唑啉衍生物
|
|
KR20060100388A
(ko)
*
|
2003-09-25 |
2006-09-20 |
아스트라제네카 아베 |
퀴나졸린 유도체
|
|
GB0322409D0
(en)
|
2003-09-25 |
2003-10-29 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
PT2213661E
(pt)
|
2003-09-26 |
2011-12-15 |
Exelixis Inc |
Moduladores de c-met e métodos de uso
|
|
US7456189B2
(en)
*
|
2003-09-30 |
2008-11-25 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
|
|
GB0326459D0
(en)
|
2003-11-13 |
2003-12-17 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
GB0330002D0
(en)
|
2003-12-24 |
2004-01-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
WO2005073224A2
(en)
|
2004-01-23 |
2005-08-11 |
Amgen Inc |
Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
|
|
JP4932495B2
(ja)
*
|
2004-01-23 |
2012-05-16 |
アムゲン インコーポレイテッド |
化合物及び使用方法
|
|
JP5032851B2
(ja)
|
2004-02-03 |
2012-09-26 |
アストラゼネカ アクチボラグ |
キナゾリン誘導体
|
|
JP4934432B2
(ja)
*
|
2004-02-19 |
2012-05-16 |
レクサン ファーマシューティカルズ インコーポレイテッド |
キナゾリン誘導体およびキナゾリン誘導体の治療への使用
|
|
EP2332990A1
(en)
|
2004-03-19 |
2011-06-15 |
Imclone LLC |
Human anti-epidermal growth factor receptor antibody
|
|
RS52545B
(sr)
|
2004-04-07 |
2013-04-30 |
Novartis Ag |
Inhibitori protein apoptoze (iap)
|
|
WO2005107747A2
(en)
|
2004-05-06 |
2005-11-17 |
Bioresponse, Llc |
Diindolymethane formulations for the treatment of leiomyomas
|
|
CN1972688B
(zh)
|
2004-05-06 |
2012-06-27 |
沃尼尔·朗伯有限责任公司 |
4-苯胺基-喹唑啉-6-基-酰胺类化合物
|
|
GB0512324D0
(en)
|
2005-06-16 |
2005-07-27 |
Novartis Ag |
Organic compounds
|
|
JP2008513426A
(ja)
*
|
2004-09-20 |
2008-05-01 |
バイオリポックス エービー |
炎症の治療に有用なピラゾール化合物
|
|
US20070054916A1
(en)
*
|
2004-10-01 |
2007-03-08 |
Amgen Inc. |
Aryl nitrogen-containing bicyclic compounds and methods of use
|
|
EP1802591B1
(en)
|
2004-10-12 |
2012-01-11 |
AstraZeneca AB |
Quinazoline derivatives
|
|
CN101083996A
(zh)
*
|
2004-10-28 |
2007-12-05 |
Irm责任有限公司 |
作为hedgehog途径调节剂的化合物和组合物
|
|
MX2007006230A
(es)
*
|
2004-11-30 |
2007-07-25 |
Amgen Inc |
Quinolinas y analogos de quinazolinas y su uso como medicamentos para tratar cancer.
|
|
EP1838712B8
(en)
|
2004-12-14 |
2011-10-12 |
AstraZeneca AB |
Pyrazolopyrimidine compounds as antitumor agents
|
|
KR100735639B1
(ko)
*
|
2004-12-29 |
2007-07-04 |
한미약품 주식회사 |
암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
|
|
CA2593084C
(en)
|
2004-12-30 |
2014-03-18 |
Bioresponse, Llc |
Use of diindolylmethane-related indoles for the treatment and prevention of respiratory syncytial virus associated conditions
|
|
US20060188498A1
(en)
*
|
2005-02-18 |
2006-08-24 |
Genentech, Inc. |
Methods of using death receptor agonists and EGFR inhibitors
|
|
US20090155247A1
(en)
*
|
2005-02-18 |
2009-06-18 |
Ashkenazi Avi J |
Methods of Using Death Receptor Agonists and EGFR Inhibitors
|
|
KR100910333B1
(ko)
*
|
2005-02-23 |
2009-07-31 |
시오노기세이야쿠가부시키가이샤 |
타이로신 키나아제 억제 활성을 갖는 퀴나졸린 유도체
|
|
MX2007010399A
(es)
*
|
2005-02-26 |
2007-09-25 |
Astrazeneca Ab |
Derivados de quinazolina en la forma de inhibidores de cinasa de tirosina.
|
|
JO2787B1
(en)
*
|
2005-04-27 |
2014-03-15 |
امجين إنك, |
Alternative amide derivatives and methods of use
|
|
GB0508715D0
(en)
*
|
2005-04-29 |
2005-06-08 |
Astrazeneca Ab |
Chemical compounds
|
|
WO2006119674A1
(en)
*
|
2005-05-12 |
2006-11-16 |
Wenlin Huang |
The preparation process of quinazoline derivatives and application for the manufacture for the treatment of tumor disease
|
|
WO2006119673A1
(fr)
*
|
2005-05-12 |
2006-11-16 |
Wenlin Huang |
Procede de preparation de derives de quinazoline et application pour la fabrication pour le traitement d’une maladie tumorale
|
|
WO2006119675A1
(en)
*
|
2005-05-12 |
2006-11-16 |
Wenlin Huang |
The preparation process of quinazoline derivatives and application for the manufacture for the treatment of tumor disease
|
|
WO2006119676A1
(en)
*
|
2005-05-12 |
2006-11-16 |
Wenlin Huang |
The preparation process of quinazoline derivatives and application for the manufacture for the treatment of tumor disease
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
CA2612449A1
(en)
|
2005-06-17 |
2006-12-28 |
Imclone Systems Incorporated |
Receptor antagonists for treatment of metastatic bone cancer
|
|
EP1928843A1
(en)
*
|
2005-08-22 |
2008-06-11 |
Amgen, Inc |
Bis-aryl urea compounds for the treatment of protein kinase-mediated diseaes
|
|
ATE520979T1
(de)
|
2005-08-24 |
2011-09-15 |
Bristol Myers Squibb Co |
Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors
|
|
WO2007034144A1
(en)
|
2005-09-20 |
2007-03-29 |
Astrazeneca Ab |
4- (ih-indazol-s-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer
|
|
TW200800911A
(en)
*
|
2005-10-20 |
2008-01-01 |
Biolipox Ab |
Pyrazoles useful in the treatment of inflammation
|
|
ZA200803636B
(en)
*
|
2005-10-31 |
2009-10-28 |
Biolipox Ab |
Triazole compounds as lipoxygenase inhibitors
|
|
TW200732320A
(en)
*
|
2005-10-31 |
2007-09-01 |
Biolipox Ab |
Pyrazoles useful in the treatment of inflammation
|
|
WO2007052000A1
(en)
*
|
2005-11-01 |
2007-05-10 |
Biolipox Ab |
Pyrazoles useful in the treatment of inflammation
|
|
CA2833706C
(en)
|
2005-11-11 |
2014-10-21 |
Boehringer Ingelheim International Gmbh |
Quinazoline derivatives for the treatment of cancer diseases
|
|
ES2364901T3
(es)
|
2005-11-15 |
2011-09-16 |
Array Biopharma, Inc. |
Procesos e intermedios para la preparación de derivados de n4-fenil-quinazolin-4-amina.
|
|
RU2487711C2
(ru)
|
2005-11-21 |
2013-07-20 |
Новартис Аг |
Лечение нейроэндокринных опухолей
|
|
CN101003514A
(zh)
|
2006-01-20 |
2007-07-25 |
上海艾力斯医药科技有限公司 |
喹唑啉衍生物、其制备方法及用途
|
|
US20090076075A1
(en)
*
|
2006-03-02 |
2009-03-19 |
Frederic Henri Jung |
Quinoline derivatives
|
|
UY30183A1
(es)
|
2006-03-02 |
2007-10-31 |
Astrazeneca Ab |
Derivados de quinolina
|
|
GB0605120D0
(en)
|
2006-03-14 |
2006-04-26 |
Novartis Ag |
Organic Compounds
|
|
DE102006012251A1
(de)
*
|
2006-03-15 |
2007-11-08 |
Grünenthal GmbH |
Substituierte 4-Amino-chinazolin-Derivate und ihre Verwendung zur Herstellung von Arzneimitteln
|
|
US20070231298A1
(en)
*
|
2006-03-31 |
2007-10-04 |
Cell Genesys, Inc. |
Cytokine-expressing cancer immunotherapy combinations
|
|
EP2606890A1
(en)
|
2006-04-05 |
2013-06-26 |
Novartis AG |
Combinations comprising BCR-ABL/C-KIT/PDGF-R TK inhibitors for treating cancer
|
|
CA2645633A1
(en)
|
2006-04-05 |
2007-11-01 |
Novartis Ag |
Combinations of therapeutic agents for treating cancer
|
|
EA200802058A1
(ru)
|
2006-05-09 |
2009-06-30 |
Пфайзер Продактс Инк. |
Производные циклоалкиламинокислот и их фармацевтические композиции
|
|
MX2008014292A
(es)
|
2006-05-09 |
2008-11-18 |
Novartis Ag |
Combinacion que comprende un quelante de hierro y un agente anti-neoplastico, y uso de la misma.
|
|
AU2007249762A1
(en)
*
|
2006-05-15 |
2007-11-22 |
Senex Biotechnology, Inc |
Identification of CDKI pathway inhibitors
|
|
WO2008002039A1
(en)
*
|
2006-06-28 |
2008-01-03 |
Hanmi Pharm. Co., Ltd. |
Quinazoline derivatives for inhibiting the growth of cancer cell
|
|
KR100929146B1
(ko)
*
|
2006-06-28 |
2009-12-01 |
한미약품 주식회사 |
암세포 성장 억제 효과를 갖는 퀴나졸린 유도체
|
|
US9259426B2
(en)
|
2006-07-20 |
2016-02-16 |
Gilead Sciences, Inc. |
4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
|
|
WO2008009077A2
(en)
|
2006-07-20 |
2008-01-24 |
Gilead Sciences, Inc. |
4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections
|
|
WO2008020302A2
(en)
*
|
2006-08-17 |
2008-02-21 |
Pfizer Products Inc. |
Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
|
|
US20100008910A1
(en)
|
2006-09-12 |
2010-01-14 |
John Chant |
Methods and compositions for the diagnosis and treatment of cancer
|
|
AU2007299080B2
(en)
*
|
2006-09-18 |
2013-04-18 |
Boehringer Ingelheim International Gmbh |
Method for treating cancer harboring EGFR mutations
|
|
WO2008037477A1
(en)
|
2006-09-29 |
2008-04-03 |
Novartis Ag |
Pyrazolopyrimidines as p13k lipid kinase inhibitors
|
|
WO2008057280A1
(en)
|
2006-10-27 |
2008-05-15 |
Amgen Inc. |
Multi-cyclic compounds and methods of use
|
|
BRPI0717753B1
(pt)
|
2006-10-27 |
2022-04-12 |
Bioresponse, Llc |
Uso de uma composição compreendendo 50-250 mg de um ou mais indóis relacionados com dim e um ou mais agentes anti-protozoários, e, composição
|
|
EP1921070A1
(de)
*
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
|
|
US20110008347A1
(en)
*
|
2006-12-01 |
2011-01-13 |
Agency For Science ,Technology And Research |
Cancer-related protein kinases
|
|
EP2118075A1
(de)
*
|
2007-02-06 |
2009-11-18 |
Boehringer Ingelheim International GmbH |
Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
|
|
EP1956010A1
(de)
*
|
2007-02-06 |
2008-08-13 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel,deren Verwendung und Verfahren zu ihrer Herstellung
|
|
BRPI0807812A2
(pt)
|
2007-02-15 |
2020-06-23 |
Novartis Ag |
Combinações de lbh589 com outros agentes terapêuticos para tratar câncer
|
|
BRPI0810411B8
(pt)
|
2007-04-18 |
2021-05-25 |
Pfizer Prod Inc |
derivados de sulfonil amida para o tratamento de crescimento celular anormal, seu sos, bem como composição farmacêutica
|
|
EP2152672A1
(en)
*
|
2007-05-24 |
2010-02-17 |
Bayer Schering Pharma Aktiengesellschaft |
Novel sulphoximine-substituted quinazoline and quinazoline derivatives as kinase inhibitors
|
|
UY31137A1
(es)
*
|
2007-06-14 |
2009-01-05 |
Smithkline Beecham Corp |
Derivados de quinazolina como inhibidores de la pi3 quinasa
|
|
WO2009058267A2
(en)
*
|
2007-10-29 |
2009-05-07 |
Amgen Inc. |
Benzomorpholine derivatives and methods of use
|
|
WO2009057139A2
(en)
|
2007-10-29 |
2009-05-07 |
Natco Pharma Limited |
Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents
|
|
US20110053991A1
(en)
*
|
2007-11-19 |
2011-03-03 |
Gore Lia |
Treatment of Histone Deacetylase Mediated Disorders
|
|
EP2072502A1
(de)
*
|
2007-12-20 |
2009-06-24 |
Bayer Schering Pharma Aktiengesellschaft |
Sulfoximid-substituierte Chinolin- und Chinazolinderivate als Kinase-Inhibitoren
|
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
|
|
CA2711582A1
(en)
*
|
2008-02-07 |
2009-08-13 |
Boehringer Ingelheim International Gmbh |
Spirocyclic heterocycles, formulations containing said compounds, use thereof and processes for the preparation thereof
|
|
WO2009118292A1
(en)
|
2008-03-24 |
2009-10-01 |
Novartis Ag |
Arylsulfonamide-based matrix metalloprotease inhibitors
|
|
NZ588069A
(en)
|
2008-03-26 |
2012-06-29 |
Novartis Ag |
Hydroxamate-based inhibitors of deacetylases b
|
|
EP2303276B1
(en)
|
2008-05-13 |
2013-11-13 |
AstraZeneca AB |
Fumarate salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline
|
|
CA2733153C
(en)
*
|
2008-08-08 |
2016-11-08 |
Boehringer Ingelheim International Gmbh |
Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
|
|
WO2010026121A1
(en)
|
2008-09-02 |
2010-03-11 |
Novartis Ag |
Bicyclic kinase inhibitors
|
|
EP2344161B1
(en)
|
2008-10-16 |
2018-12-19 |
Celator Pharmaceuticals, Inc. |
Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab
|
|
WO2010054264A1
(en)
|
2008-11-07 |
2010-05-14 |
Triact Therapeutics, Inc. |
Use of catecholic butane derivatives in cancer therapy
|
|
CN102256942B
(zh)
|
2008-12-18 |
2013-07-24 |
诺瓦提斯公司 |
1-(4-{1-[(e)-4-环己基-3-三氟甲基-苄氧基亚氨基]-乙基}-2-乙基-苄基)-氮杂环丁烷-3-甲酸的多晶型物
|
|
CA2747558A1
(en)
|
2008-12-18 |
2010-07-15 |
Novartis Ag |
New salts
|
|
PT2676953T
(pt)
|
2008-12-18 |
2017-06-29 |
Novartis Ag |
Sal hemifumarato de ácido 1-[4-[1-(4-ciclo-hexil-3-trifluorometil-benziloxi-imino)-etil]-2-etil-benzil]-azetidino-3-carboxílico para utilização no tratamento de doenças mediadas por linfócitos
|
|
SG173014A1
(en)
|
2009-01-16 |
2011-08-29 |
Exelixis Inc |
Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl)-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
|
|
WO2010083617A1
(en)
|
2009-01-21 |
2010-07-29 |
Oncalis Ag |
Pyrazolopyrimidines as protein kinase inhibitors
|
|
PT2391366E
(pt)
|
2009-01-29 |
2013-02-05 |
Novartis Ag |
Benzimidazoles substituídos para o tratamento de astrocitomas
|
|
WO2010099139A2
(en)
|
2009-02-25 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Combination anti-cancer therapy
|
|
US20110171124A1
(en)
|
2009-02-26 |
2011-07-14 |
Osi Pharmaceuticals, Inc. |
In situ methods for monitoring the EMT status of tumor cells in vivo
|
|
EP2401614A1
(en)
|
2009-02-27 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
JP2012519282A
(ja)
|
2009-02-27 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
|
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
EP2408479A1
(en)
|
2009-03-18 |
2012-01-25 |
OSI Pharmaceuticals, LLC |
Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor
|
|
CN104447995A
(zh)
|
2009-03-20 |
2015-03-25 |
霍夫曼-拉罗奇有限公司 |
双特异性抗-her抗体
|
|
UY32730A
(es)
|
2009-06-26 |
2011-01-31 |
Novartis Ag |
Inhibidores de cyp17
|
|
PL2451445T3
(pl)
|
2009-07-06 |
2019-09-30 |
Boehringer Ingelheim International Gmbh |
Sposób suszenia BIBW2992, jego soli i stałych preparatów farmaceutycznych zawierających tę substancję czynną
|
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
|
JP5781510B2
(ja)
|
2009-08-12 |
2015-09-24 |
ノバルティス アーゲー |
ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用
|
|
PE20121148A1
(es)
|
2009-08-17 |
2012-09-07 |
Intellikine Llc |
Compuestos heterociclicos y usos de los mismos
|
|
JP5775871B2
(ja)
|
2009-08-20 |
2015-09-09 |
ノバルティス アーゲー |
ヘテロ環式オキシム化合物
|
|
WO2011023677A1
(en)
|
2009-08-26 |
2011-03-03 |
Novartis Ag |
Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
|
|
CA2772194A1
(en)
|
2009-09-01 |
2011-03-10 |
Pfizer Inc. |
Benzimidazole derivatives
|
|
WO2011029915A1
(en)
|
2009-09-10 |
2011-03-17 |
Novartis Ag |
Ether derivatives of bicyclic heteroaryls
|
|
EP2494070A2
(en)
|
2009-10-30 |
2012-09-05 |
Bristol-Myers Squibb Company |
Methods for treating cancer in patients having igf-1r inhibitor resistance
|
|
JP5466767B2
(ja)
|
2009-11-04 |
2014-04-09 |
ノバルティス アーゲー |
Ｍｅｋ阻害剤として有用なヘテロ環式スルホンアミド誘導体
|
|
KR20120103587A
(ko)
|
2009-11-12 |
2012-09-19 |
제넨테크, 인크. |
수상돌기 소극 밀도를 증진시키는 방법
|
|
US20120316187A1
(en)
|
2009-11-13 |
2012-12-13 |
Pangaea Biotech, S.L. |
Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
|
|
AU2010321533A1
(en)
|
2009-11-23 |
2012-05-31 |
Cerulean Pharma Inc. |
Cyclodextrin-based polymers for therapeutic delivery
|
|
WO2011064211A1
(en)
|
2009-11-25 |
2011-06-03 |
Novartis Ag |
Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
|
|
CA2781218A1
(en)
|
2009-12-08 |
2011-06-16 |
Novartis Ag |
Heterocyclic sulfonamide derivatives
|
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
|
CU24130B1
(es)
|
2009-12-22 |
2015-09-29 |
Novartis Ag |
Isoquinolinonas y quinazolinonas sustituidas
|
|
EP2523957A1
(en)
|
2010-01-12 |
2012-11-21 |
F. Hoffmann-La Roche AG |
Tricyclic heterocyclic compounds, compositions and methods of use thereof
|
|
US20110178287A1
(en)
|
2010-01-19 |
2011-07-21 |
Cerulean Pharma Inc. |
Cyclodextrin-based polymers for therapeutic delivery
|
|
DK2536748T3
(da)
|
2010-02-18 |
2014-10-13 |
Genentech Inc |
Neuregulin-antagonister og anvendelse deraf ved behandling af kræft
|
|
CA2793024A1
(en)
|
2010-03-17 |
2011-09-22 |
F. Hoffmann-La Roche Ag |
Imidazopyridine compounds, compositions and methods of use
|
|
US20110237686A1
(en)
|
2010-03-26 |
2011-09-29 |
Cerulean Pharma Inc |
Formulations and methods of use
|
|
MX2012011887A
(es)
|
2010-04-16 |
2012-11-30 |
Genentech Inc |
Foxo 3a como biomarcador predictivo para la eficacia del inhibidor de la via de quinasa pi3k/akt.
|
|
WO2011157793A1
(en)
|
2010-06-17 |
2011-12-22 |
Novartis Ag |
Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
|
|
CN102947274A
(zh)
|
2010-06-17 |
2013-02-27 |
诺瓦提斯公司 |
联苯基取代的1,3-二氢-苯并咪唑-2-亚基胺衍生物
|
|
UA112517C2
(uk)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
Тетрагідропіридопіримідинові похідні
|
|
KR20130103734A
(ko)
|
2010-08-31 |
2013-09-24 |
제넨테크, 인크. |
바이오마커 및 치료 방법
|
|
MX2013003019A
(es)
|
2010-09-15 |
2013-05-28 |
Hoffmann La Roche |
Compuestos de azabenzotiazol, composiciones y metodos de uso.
|
|
US8946260B2
(en)
|
2010-09-16 |
2015-02-03 |
Novartis Ag |
17α-hydroxylase/C17,20-lyase inhibitors
|
|
JP5802756B2
(ja)
|
2010-10-20 |
2015-11-04 |
ファイザー・インク |
スムーズンド受容体モジュレーターとしてのピリジン−２−誘導体
|
|
MX2013005445A
(es)
|
2010-11-19 |
2013-07-29 |
Hoffmann La Roche |
Pirazolopiridinas y el uso de pirazolopiridinas como inhibidores de tirosina cinasa 2 (tyk2).
|
|
CN102485735B
(zh)
*
|
2010-12-02 |
2014-09-24 |
东莞南方医大代谢医学研发有限公司 |
6-果糖氨-4-芳胺基喹唑啉衍生物及其用途
|
|
AU2011346567A1
(en)
|
2010-12-21 |
2013-07-25 |
Novartis Ag |
Bi-heteroaryl compounds as Vps34 inhibitors
|
|
EP2468883A1
(en)
|
2010-12-22 |
2012-06-27 |
Pangaea Biotech S.L. |
Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
|
|
WO2012085176A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
|
|
US9134297B2
(en)
|
2011-01-11 |
2015-09-15 |
Icahn School Of Medicine At Mount Sinai |
Method and compositions for treating cancer and related methods
|
|
WO2012107500A1
(en)
|
2011-02-10 |
2012-08-16 |
Novartis Ag |
[1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
|
WO2012112567A1
(en)
*
|
2011-02-15 |
2012-08-23 |
Georgetown University |
Small molecule inhibitors of agbl2
|
|
CN102153519B
(zh)
*
|
2011-02-18 |
2012-10-24 |
上海长林化学科技有限公司 |
一类喹唑啉衍生物的制备方法
|
|
EP2492688A1
(en)
|
2011-02-23 |
2012-08-29 |
Pangaea Biotech, S.A. |
Molecular biomarkers for predicting response to antitumor treatment in lung cancer
|
|
WO2012116237A2
(en)
|
2011-02-23 |
2012-08-30 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
|
JP2014507465A
(ja)
|
2011-03-08 |
2014-03-27 |
ノバルティス アーゲー |
フルオロフェニル二環式ヘテロアリール化合物
|
|
WO2012129145A1
(en)
|
2011-03-18 |
2012-09-27 |
OSI Pharmaceuticals, LLC |
Nscle combination therapy
|
|
EP2702173A1
(en)
|
2011-04-25 |
2014-03-05 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
|
GB201106870D0
(en)
|
2011-04-26 |
2011-06-01 |
Univ Belfast |
Marker
|
|
AU2012249421B9
(en)
|
2011-04-28 |
2015-10-22 |
Novartis Ag |
17alpha-hydroxylase/C17,20-lyase inhibitors
|
|
BR112013031201A2
(pt)
|
2011-06-09 |
2017-01-31 |
Novartis Ag |
derivados de sulfonamida heterocíclicos, composição farmacêutica os compreendendo, uso, processo para a fabricação de (r)-n-(4,5-difluoro-6-((2-fluoro-4-iodofenil)amino)benzofuran-7-il)-1-(2,3-di-idroxipropil)ciclopropano-5 1-sulfonamida e kit
|
|
WO2012175520A1
(en)
|
2011-06-20 |
2012-12-27 |
Novartis Ag |
Hydroxy substituted isoquinolinone derivatives
|
|
EP2721007B1
(en)
|
2011-06-20 |
2015-04-29 |
Novartis AG |
Cyclohexyl isoquinolinone compounds
|
|
JP2014518256A
(ja)
|
2011-06-27 |
2014-07-28 |
ノバルティス アーゲー |
テトラヒドロ−ピリド−ピリミジン誘導体の固体形態および塩類
|
|
WO2013007768A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
|
|
WO2013007765A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Fused tricyclic compounds for use as inhibitors of janus kinases
|
|
CN103889976A
(zh)
|
2011-08-12 |
2014-06-25 |
弗·哈夫曼-拉罗切有限公司 |
吲唑化合物、组合物及使用方法
|
|
US12194002B2
(en)
|
2011-08-17 |
2025-01-14 |
Dennis Brown |
Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol
|
|
US20140363438A1
(en)
|
2011-08-17 |
2014-12-11 |
Genentech, Inc. |
Neuregulin antibodies and uses thereof
|
|
SG2014011316A
(en)
|
2011-08-31 |
2014-06-27 |
Genentech Inc |
Diagnostic markers
|
|
EA026655B1
(ru)
|
2011-09-15 |
2017-05-31 |
Новартис Аг |
6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
|
|
JP2014526538A
(ja)
|
2011-09-20 |
2014-10-06 |
エフ．ホフマン−ラ ロシュ アーゲー |
イミダゾピリジン化合物、組成物及び使用方法
|
|
KR20140059246A
(ko)
|
2011-09-22 |
2014-05-15 |
화이자 인코포레이티드 |
피롤로피리미딘 및 퓨린 유도체
|
|
JP2014531213A
(ja)
|
2011-09-30 |
2014-11-27 |
ジェネンテック， インコーポレイテッド |
上皮又は間葉の表現型の診断用メチル化マーカー、及び腫瘍又は腫瘍細胞におけるｅｇｆｒキナーゼ阻害薬に対する応答
|
|
WO2013056069A1
(en)
|
2011-10-13 |
2013-04-18 |
Bristol-Myers Squibb Company |
Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
|
|
CN103086984A
(zh)
*
|
2011-11-03 |
2013-05-08 |
南京大学 |
一类4-苯氨基喹唑啉类衍生物及其制备方法与用途
|
|
JP5992054B2
(ja)
|
2011-11-29 |
2016-09-14 |
ノバルティス アーゲー |
ピラゾロピロリジン化合物
|
|
RU2014126098A
(ru)
|
2011-11-30 |
2016-01-27 |
Дженентек, Инк. |
МУТАЦИИ ErbB3 ПРИ РАКЕ
|
|
US9408885B2
(en)
|
2011-12-01 |
2016-08-09 |
Vib Vzw |
Combinations of therapeutic agents for treating melanoma
|
|
JP5903499B2
(ja)
|
2011-12-22 |
2016-04-13 |
ノバルティス アーゲー |
ジヒドロ−ベンゾ−オキサジンおよびジヒドロ−ピリド−オキサジン誘導体
|
|
WO2013093850A1
(en)
|
2011-12-22 |
2013-06-27 |
Novartis Ag |
Quinoline derivatives
|
|
MX2014007732A
(es)
|
2011-12-23 |
2015-01-12 |
Novartis Ag |
Compuestos para inhibir la interaccion de bcl2 con los mismos componentes de enlace.
|
|
US20130178520A1
(en)
|
2011-12-23 |
2013-07-11 |
Duke University |
Methods of treatment using arylcyclopropylamine compounds
|
|
EP2794592A1
(en)
|
2011-12-23 |
2014-10-29 |
Novartis AG |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
|
EP2794588A1
(en)
|
2011-12-23 |
2014-10-29 |
Novartis AG |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
|
JP2015503518A
(ja)
|
2011-12-23 |
2015-02-02 |
ノバルティス アーゲー |
Ｂｃｌ２と結合相手の相互作用を阻害するための化合物
|
|
BR112014015442A8
(pt)
|
2011-12-23 |
2017-07-04 |
Novartis Ag |
compostos e composições para inibir a interação de bcl2 com parceiros de ligação
|
|
US8785459B2
(en)
*
|
2011-12-27 |
2014-07-22 |
Development Center For Biotechnology |
Quinazoline compounds as kinase inhibitors
|
|
TWI557109B
(zh)
*
|
2011-12-29 |
2016-11-11 |
財團法人生物技術開發中心 |
喹唑啉化合物作為激酶抑制劑及其應用
|
|
US8815926B2
(en)
|
2012-01-26 |
2014-08-26 |
Novartis Ag |
Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
|
|
CN103360382B
(zh)
*
|
2012-03-26 |
2016-04-27 |
中国科学院福建物质结构研究所 |
喹唑啉衍生物及其用途
|
|
WO2013143057A1
(zh)
|
2012-03-26 |
2013-10-03 |
中国科学院福建物质结构研究所 |
喹唑啉衍生物及用途
|
|
RU2014136886A
(ru)
|
2012-03-27 |
2016-05-20 |
Дженентек, Инк. |
Диагностика и виды лечения, связанные с ингибиторами her3
|
|
JP2015512425A
(ja)
|
2012-04-03 |
2015-04-27 |
ノバルティス アーゲー |
チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用
|
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
|
EP2855483B1
(en)
|
2012-05-24 |
2017-10-25 |
Novartis AG |
Pyrrolopyrrolidinone compounds
|
|
CN102924387B
(zh)
*
|
2012-06-13 |
2015-07-01 |
黄唯燕 |
4-(3-氯-4-甲氧基苯胺基)-6-(3,4-取代苯基)喹唑啉及盐和制法与应用
|
|
CN102702179A
(zh)
*
|
2012-06-13 |
2012-10-03 |
华南理工大学 |
4-(3-氯-4-甲氧基苯胺基)-6-(呋喃-2-基)喹唑啉类化合物或其药学上可接受的盐和制备方法与应用
|
|
CN102702116B
(zh)
*
|
2012-06-13 |
2014-12-31 |
华南理工大学 |
4-(3-氯-4-甲氧基苯胺基)-6-(3-胺基苯基)喹唑啉类化合物或其药学上可接受的盐和制备方法与应用
|
|
JP6427097B2
(ja)
|
2012-06-15 |
2018-11-21 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． |
癌を処置するための組成物および該組成物を製造するための方法
|
|
WO2013190089A1
(en)
|
2012-06-21 |
2013-12-27 |
Pangaea Biotech, S.L. |
Molecular biomarkers for predicting outcome in lung cancer
|
|
EP2879675B1
(en)
|
2012-08-06 |
2019-11-13 |
Duke University |
Compounds and methods for targeting hsp90
|
|
CA2888803A1
(en)
|
2012-11-05 |
2014-05-08 |
Jooeun Bae |
Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
|
|
TW201422625A
(zh)
|
2012-11-26 |
2014-06-16 |
Novartis Ag |
二氫－吡啶并－□衍生物之固體形式
|
|
WO2014115080A1
(en)
|
2013-01-22 |
2014-07-31 |
Novartis Ag |
Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
|
|
US9403827B2
(en)
|
2013-01-22 |
2016-08-02 |
Novartis Ag |
Substituted purinone compounds
|
|
DK2958943T3
(da)
|
2013-02-20 |
2019-12-09 |
Univ Pennsylvania |
Behandling af cancer ved anvendelse af humaniseret anti-EGFRvIII kimær antigenreceptor
|
|
WO2014128612A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Quinazolin-4-one derivatives
|
|
EP2958592A1
(en)
|
2013-02-22 |
2015-12-30 |
F. Hoffmann-La Roche AG |
Methods of treating cancer and preventing drug resistance
|
|
JP6255038B2
(ja)
|
2013-02-26 |
2017-12-27 |
トリアクト セラピューティクス，インク． |
癌治療
|
|
CN105209456B
(zh)
|
2013-03-06 |
2018-05-08 |
阿斯利康(瑞典)有限公司 |
表皮生长因子受体的活化突变形式的喹唑啉抑制剂
|
|
KR20150123250A
(ko)
|
2013-03-06 |
2015-11-03 |
제넨테크, 인크. |
암 약물 내성의 치료 및 예방 방법
|
|
WO2014139326A1
(en)
|
2013-03-13 |
2014-09-18 |
Genentech, Inc. |
Pyrazolo compounds and uses thereof
|
|
JP2016515132A
(ja)
|
2013-03-14 |
2016-05-26 |
ジェネンテック， インコーポレイテッド |
Ｍｅｋ阻害剤化合物のｈｅｒ３／ｅｇｆｒ阻害剤化合物との組み合わせ及び使用方法
|
|
KR20150127216A
(ko)
|
2013-03-14 |
2015-11-16 |
제넨테크, 인크. |
암의 치료 및 암 약물 내성의 예방 방법
|
|
EP2968340A4
(en)
|
2013-03-15 |
2016-08-10 |
Intellikine Llc |
COMBINING KINASE INHIBITORS AND USES THEREOF
|
|
WO2014144850A1
(en)
|
2013-03-15 |
2014-09-18 |
Genentech, Inc. |
Methods of treating cancer and preventing cancer drug resistance
|
|
EP2976085A1
(en)
|
2013-03-21 |
2016-01-27 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
|
|
WO2014155268A2
(en)
|
2013-03-25 |
2014-10-02 |
Novartis Ag |
Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
|
|
US20150018376A1
(en)
|
2013-05-17 |
2015-01-15 |
Novartis Ag |
Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
UY35675A
(es)
|
2013-07-24 |
2015-02-27 |
Novartis Ag |
Derivados sustituidos de quinazolin-4-ona
|
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
|
WO2015022664A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
|
WO2015022663A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
|
MX2016002794A
(es)
|
2013-09-05 |
2016-09-13 |
Genentech Inc |
Compuestos antiproliferativos.
|
|
US9381246B2
(en)
|
2013-09-09 |
2016-07-05 |
Triact Therapeutics, Inc. |
Cancer therapy
|
|
US9657007B2
(en)
|
2013-09-22 |
2017-05-23 |
Calitor Sciences, Llc |
Substituted aminopyrimidine compounds and methods of use
|
|
TW201605857A
(zh)
|
2013-10-03 |
2016-02-16 |
赫孚孟拉羅股份公司 |
Ｃｄｋ８之醫療性抑制劑及其用途
|
|
CN105744954B
(zh)
|
2013-10-18 |
2021-03-05 |
豪夫迈·罗氏有限公司 |
抗rspo2和/或抗rspo3抗体及其用途
|
|
UA115388C2
(uk)
|
2013-11-21 |
2017-10-25 |
Пфайзер Інк. |
2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
|
|
WO2015084804A1
(en)
|
2013-12-03 |
2015-06-11 |
Novartis Ag |
Combination of mdm2 inhibitor and braf inhibitor and their use
|
|
WO2015095404A2
(en)
|
2013-12-17 |
2015-06-25 |
Genentech, Inc. |
Methods of treating cancers using pd-1 axis binding antagonists and taxanes
|
|
AU2014364606A1
(en)
|
2013-12-17 |
2016-07-07 |
Genentech, Inc. |
Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
|
|
TWI624461B
(zh)
*
|
2013-12-19 |
2018-05-21 |
財團法人生物技術開發中心 |
喹唑啉化合物，其製備方法及用途
|
|
US9382331B2
(en)
|
2013-12-27 |
2016-07-05 |
Development Center For Biotechnology |
Alpha-enolase specific antibodies and methods of uses in cancer therapy
|
|
US9242965B2
(en)
|
2013-12-31 |
2016-01-26 |
Boehringer Ingelheim International Gmbh |
Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
|
|
WO2015128873A1
(en)
*
|
2014-02-27 |
2015-09-03 |
Council Of Scientific & Industrial Research |
"6-aryl-4-phenylamino-quinazoline analogs as phosphoinositide-3-kinase inhibitors"
|
|
EP3122900A1
(en)
|
2014-03-24 |
2017-02-01 |
F. Hoffmann-La Roche AG |
Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
|
|
US10000469B2
(en)
|
2014-03-25 |
2018-06-19 |
Duke University |
Heat shock protein 70 (hsp-70) receptor ligands
|
|
WO2015145388A2
(en)
|
2014-03-27 |
2015-10-01 |
Novartis Ag |
Methods of treating colorectal cancers harboring upstream wnt pathway mutations
|
|
MX2016012574A
(es)
|
2014-03-28 |
2017-09-26 |
Calitor Sciences Llc |
Compuestos heteroarilo sustituidos y metodos de uso.
|
|
RU2016142476A
(ru)
|
2014-03-31 |
2018-05-07 |
Дженентек, Инк. |
Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
|
|
EP3126394B1
(en)
|
2014-03-31 |
2019-10-30 |
F.Hoffmann-La Roche Ag |
Anti-ox40 antibodies and methods of use
|
|
KR20160132496A
(ko)
|
2014-04-03 |
2016-11-18 |
인빅터스 온콜로지 피비티. 엘티디. |
초분자 조합 치료제
|
|
WO2015155624A1
(en)
|
2014-04-10 |
2015-10-15 |
Pfizer Inc. |
Dihydropyrrolopyrimidine derivatives
|
|
US20170027940A1
(en)
|
2014-04-10 |
2017-02-02 |
Stichting Het Nederlands Kanker Instituut |
Method for treating cancer
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
EP3556757A1
(en)
|
2014-04-30 |
2019-10-23 |
Pfizer Inc |
Cycloalkyl-linked diheterocycle derivatives
|
|
WO2016001789A1
(en)
|
2014-06-30 |
2016-01-07 |
Pfizer Inc. |
Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
|
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
|
ES2831416T3
(es)
|
2014-07-31 |
2021-06-08 |
Novartis Ag |
Terapia de combinación de un inhibidor de MET y un inhibidor de EGFR
|
|
EP3189046B1
(en)
|
2014-09-05 |
2020-08-26 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
|
WO2016044694A1
(en)
|
2014-09-19 |
2016-03-24 |
Genentech, Inc. |
Use of cbp/ep300 and bet inhibitors for treatment of cancer
|
|
EP3204379B1
(en)
|
2014-10-10 |
2019-03-06 |
Genentech, Inc. |
Pyrrolidine amide compounds as histone demethylase inhibitors
|
|
MX2017005751A
(es)
|
2014-11-03 |
2018-04-10 |
Genentech Inc |
Métodos y biomarcadores para predecir la eficacia y evaluación de un tratamiento con agonista de ox40.
|
|
EP3215850B1
(en)
|
2014-11-03 |
2019-07-03 |
F. Hoffmann-La Roche AG |
Assays for detecting t cell immune subsets and methods of use thereof
|
|
KR20170072343A
(ko)
|
2014-11-06 |
2017-06-26 |
제넨테크, 인크. |
Ox40 결합 효능제 및 tigit 억제제를 포함하는 병용 요법
|
|
MA40940A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
|
WO2016077375A1
(en)
|
2014-11-10 |
2016-05-19 |
Genentech, Inc. |
Bromodomain inhibitors and uses thereof
|
|
MA40943A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
|
MX2017006320A
(es)
|
2014-11-17 |
2017-08-10 |
Genentech Inc |
Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1.
|
|
US9763922B2
(en)
|
2014-11-27 |
2017-09-19 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
|
CA2969974C
(en)
|
2014-12-15 |
2020-08-04 |
The Regents Of The University Of Michigan |
Small molecule inhibitors of egfr and pi3k
|
|
BR112017010788A2
(pt)
|
2014-12-23 |
2017-12-26 |
Genentech Inc |
métodos de identificação de um paciente com câncer e de identificação de um paciente que sofre de câncer que pode beneficiar da administração de um antagonista de vegf, método de tratamento de um paciente com câncer e método para determinar o estágio de câncer de ovário
|
|
WO2016105503A1
(en)
|
2014-12-24 |
2016-06-30 |
Genentech, Inc. |
Therapeutic, diagnostic and prognostic methods for cancer of the bladder
|
|
JP2018503373A
(ja)
|
2014-12-30 |
2018-02-08 |
ジェネンテック， インコーポレイテッド |
がんの予後診断及び治療のための方法及び組成物
|
|
EP3242872B1
(en)
|
2015-01-09 |
2019-07-03 |
Genentech, Inc. |
(piperidin-3-yl)(naphthalen-2-yl)methanone derivatives and related compounds as inhibitors of the histone demethylase kdm2b for the treatment of cancer
|
|
EP3242874B1
(en)
|
2015-01-09 |
2018-10-31 |
Genentech, Inc. |
Pyridazinone derivatives and their use in the treatment of cancer
|
|
EP3242875B1
(en)
|
2015-01-09 |
2022-02-23 |
Genentech, Inc. |
4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors
|
|
US12312316B2
(en)
|
2015-01-20 |
2025-05-27 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
EP3250571B1
(en)
|
2015-01-29 |
2022-11-30 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
|
WO2016123387A1
(en)
|
2015-01-30 |
2016-08-04 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
|
MA41598A
(fr)
|
2015-02-25 |
2018-01-02 |
Constellation Pharmaceuticals Inc |
Composés thérapeutiques de pyridazine et leurs utilisations
|
|
WO2016141092A1
(en)
|
2015-03-04 |
2016-09-09 |
Gilead Sciences, Inc. |
Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds
|
|
AU2016246695A1
(en)
|
2015-04-07 |
2017-10-26 |
Genentech, Inc. |
Antigen binding complex having agonistic activity and methods of use
|
|
RS61152B2
(sr)
|
2015-05-12 |
2024-06-28 |
Hoffmann La Roche |
Terapeutski i dijagnostički postupci za lečenje raka
|
|
JP7144935B2
(ja)
|
2015-05-29 |
2022-09-30 |
ジェネンテック， インコーポレイテッド |
癌のための治療方法及び診断方法
|
|
KR20180011839A
(ko)
|
2015-06-08 |
2018-02-02 |
제넨테크, 인크. |
항-ox40 항체를 이용한 암의 치료 방법
|
|
HK1251474A1
(zh)
|
2015-06-08 |
2019-02-01 |
豪夫迈‧罗氏有限公司 |
使用抗ox40抗体和pd-1轴结合拮抗剂治疗癌症的方法
|
|
JP6896650B2
(ja)
|
2015-06-17 |
2021-06-30 |
ジェネンテック， インコーポレイテッド |
Ｐｄ−１軸結合アンタゴニスト及びタキサンを使用した局所進行性または転移性乳癌の治療方法
|
|
WO2017009751A1
(en)
|
2015-07-15 |
2017-01-19 |
Pfizer Inc. |
Pyrimidine derivatives
|
|
DK3341376T3
(da)
|
2015-08-26 |
2021-03-29 |
Fundacion Del Sector Publico Estatal Centro Nac De Investigaciones Oncologicas Carlos Iii F S P Cnio |
Kondenserede tricykliske forbindelser som proteinkinase-inhibitorer
|
|
WO2017044434A1
(en)
|
2015-09-11 |
2017-03-16 |
Sunshine Lake Pharma Co., Ltd. |
Substituted heteroaryl compounds and methods of use
|
|
CA2994858C
(en)
|
2015-09-25 |
2024-01-23 |
Genentech, Inc. |
Anti-tigit antibodies and methods of use
|
|
PL3978500T3
(pl)
|
2015-12-16 |
2024-03-11 |
Genentech, Inc. |
Sposób wytwarzania tricyklicznych związków inhibitorów pi3k
|
|
JP6949030B2
(ja)
|
2016-01-08 |
2021-10-13 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Ｐｄ−１軸結合アンタゴニスト及び抗ｃｅａ／抗ｃｄ３二重特異性抗体を用いたｃｅａ陽性がんの治療方法
|
|
JP6821693B2
(ja)
|
2016-02-29 |
2021-01-27 |
ジェネンテック， インコーポレイテッド |
がんのための治療方法及び診断方法
|
|
EP3443004A1
(en)
|
2016-04-14 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
Anti-rspo3 antibodies and methods of use
|
|
CN109154613A
(zh)
|
2016-04-15 |
2019-01-04 |
豪夫迈·罗氏有限公司 |
用于监测和治疗癌症的方法
|
|
WO2017180581A1
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
AU2017248766A1
(en)
|
2016-04-15 |
2018-11-01 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
|
WO2017184956A1
(en)
|
2016-04-22 |
2017-10-26 |
Duke University |
Compounds and methods for targeting hsp90
|
|
MA45122A
(fr)
|
2016-05-24 |
2019-04-10 |
Constellation Pharmaceuticals Inc |
Inhibiteurs hétérocycliques de cbp/ep300 et leur utilisation dans le traitement du cancer
|
|
EP3464286B1
(en)
|
2016-05-24 |
2021-08-18 |
Genentech, Inc. |
Pyrazolopyridine derivatives for the treatment of cancer
|
|
US20200129519A1
(en)
|
2016-06-08 |
2020-04-30 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
EP3478674B1
(en)
*
|
2016-06-30 |
2020-05-13 |
Gilead Sciences, Inc. |
4,6-diaminoquinazolines as cot modulators and methods of use thereof
|
|
US11046776B2
(en)
|
2016-08-05 |
2021-06-29 |
Genentech, Inc. |
Multivalent and multiepitopic antibodies having agonistic activity and methods of use
|
|
WO2018029124A1
(en)
|
2016-08-08 |
2018-02-15 |
F. Hoffmann-La Roche Ag |
Therapeutic and diagnostic methods for cancer
|
|
WO2018039203A1
(en)
|
2016-08-23 |
2018-03-01 |
Oncopep, Inc. |
Peptide vaccines and durvalumab for treating multiple myeloma
|
|
US20190209669A1
(en)
|
2016-08-23 |
2019-07-11 |
Oncopep, Inc. |
Peptide vaccines and durvalumab for treating breast cancer
|
|
EP3507288B1
(en)
|
2016-09-02 |
2020-08-26 |
Gilead Sciences, Inc. |
4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
|
|
CN109923106B
(zh)
|
2016-09-02 |
2022-09-13 |
吉利德科学公司 |
toll样受体调节剂化合物
|
|
EP4089116A1
(en)
|
2016-09-27 |
2022-11-16 |
Cero Therapeutics, Inc. |
Chimeric engulfment receptor molecules
|
|
US10927083B2
(en)
|
2016-09-29 |
2021-02-23 |
Duke University |
Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase
|
|
US10207998B2
(en)
|
2016-09-29 |
2019-02-19 |
Duke University |
Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
|
|
AU2017339517B2
(en)
|
2016-10-06 |
2024-03-14 |
Foundation Medicine, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
WO2018078143A1
(en)
|
2016-10-28 |
2018-05-03 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Means and methods for determining efficacy of anti-egfr inhibitors in colorectal cancer (crc) therapy
|
|
EP3532091A2
(en)
|
2016-10-29 |
2019-09-04 |
H. Hoffnabb-La Roche Ag |
Anti-mic antibidies and methods of use
|
|
US10202357B2
(en)
|
2016-11-09 |
2019-02-12 |
RenoTarget Therapeutics, Inc. |
Class of quinolone heterocyclic aromatic molecules for cancer treatment
|
|
WO2018119183A2
(en)
|
2016-12-22 |
2018-06-28 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
|
MX2019007646A
(es)
|
2016-12-23 |
2019-09-06 |
Arvinas Operations Inc |
Moleculas quimericas dirigidas a la proteolisis del egfr y metodos asociados de uso.
|
|
CN110546277B
(zh)
|
2017-03-01 |
2024-06-11 |
豪夫迈·罗氏有限公司 |
用于癌症的诊断和治疗方法
|
|
KR20190136076A
(ko)
|
2017-04-13 |
2019-12-09 |
에프. 호프만-라 로슈 아게 |
암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제
|
|
EA201992781A1
(ru)
|
2017-05-22 |
2020-04-01 |
Эмджен Инк. |
Ингибиторы g12c kras и способы их применения
|
|
KR102922386B1
(ko)
|
2017-07-21 |
2026-02-04 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
|
CN111295394B
(zh)
|
2017-08-11 |
2024-06-11 |
豪夫迈·罗氏有限公司 |
抗cd8抗体及其用途
|
|
AU2018329925B2
(en)
|
2017-09-08 |
2025-05-29 |
F. Hoffmann-La Roche Ag |
Diagnostic and therapeutic methods for cancer
|
|
MA50077A
(fr)
|
2017-09-08 |
2020-07-15 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
|
EP3688032B1
(en)
|
2017-09-26 |
2025-11-05 |
Cero Therapeutics Holdings, Inc. |
Chimeric engulfment receptor molecules and methods of use
|
|
WO2019083960A1
(en)
|
2017-10-24 |
2019-05-02 |
Oncopep, Inc. |
PEPTIDE VACCINES AND HDAC INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA
|
|
EP3700575A1
(en)
|
2017-10-24 |
2020-09-02 |
Oncopep, Inc. |
Peptide vaccines and pembrolizumab for treating breast cancer
|
|
WO2019084395A1
(en)
|
2017-10-27 |
2019-05-02 |
University Of Virginia Patent Foundation |
COMPOUNDS AND METHODS FOR REGULATING, LIMITING OR INHIBITING AVIL EXPRESSION
|
|
ES2984919T3
(es)
|
2017-11-06 |
2024-10-31 |
Hoffmann La Roche |
Procedimientos diagnósticos y terapéuticos para el cáncer
|
|
US10683297B2
(en)
|
2017-11-19 |
2020-06-16 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
|
JP7021356B2
(ja)
|
2017-12-21 |
2022-02-16 |
ヘフェイ インスティテューツ オブ フィジカル サイエンス， チャイニーズ アカデミー オブ サイエンシーズ |
ピリミジン誘導体系キナーゼ阻害剤類
|
|
AU2019207535B2
(en)
|
2018-01-15 |
2021-12-23 |
Epiaxis Therapeutics Pty Ltd |
Agents and methods for predicting response to therapy
|
|
AU2019209960B2
(en)
|
2018-01-20 |
2023-11-23 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
|
US11220515B2
(en)
|
2018-01-26 |
2022-01-11 |
Yale University |
Imide-based modulators of proteolysis and associated methods of use
|
|
CN111836831A
(zh)
|
2018-02-26 |
2020-10-27 |
豪夫迈·罗氏有限公司 |
用于抗tigit拮抗剂抗体和抗pd-l1拮抗剂抗体治疗的给药
|
|
RU2020135106A
(ru)
|
2018-03-28 |
2022-04-29 |
Серо Терапьютикс, Инк. |
Векторы экспрессии для химерных рецепторов поглощения, генетически модифицированные клетки-хозяева и их применения
|
|
WO2019191334A1
(en)
|
2018-03-28 |
2019-10-03 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
|
JP7444781B2
(ja)
|
2018-03-28 |
2024-03-06 |
セロ・セラピューティクス・インコーポレイテッド |
細胞免疫療法組成物およびその使用
|
|
ES2995514T3
(en)
|
2018-05-04 |
2025-02-10 |
Amgen Inc |
Kras g12c inhibitors and methods of using the same
|
|
WO2019213516A1
(en)
|
2018-05-04 |
2019-11-07 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
|
EP3790886B1
(en)
|
2018-05-10 |
2024-06-26 |
Amgen Inc. |
Kras g12c inhibitors for the treatment of cancer
|
|
CN112771177A
(zh)
|
2018-05-21 |
2021-05-07 |
纳米线科技公司 |
分子基因标签及其使用方法
|
|
ES2938987T3
(es)
|
2018-06-01 |
2023-04-18 |
Amgen Inc |
Inhibidores de KRAS G12c y métodos de uso de los mismos
|
|
US20190375749A1
(en)
|
2018-06-11 |
2019-12-12 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
|
ES3060664T3
(en)
|
2018-06-12 |
2026-03-27 |
Amgen Inc |
Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
|
|
CN112585166A
(zh)
|
2018-06-23 |
2021-03-30 |
豪夫迈·罗氏有限公司 |
用pd-1轴结合拮抗剂、铂剂和拓扑异构酶ii抑制剂治疗肺癌的方法
|
|
BR112021000673A2
(pt)
|
2018-07-18 |
2021-04-20 |
Genentech, Inc. |
métodos para tratar um indivíduo com câncer de pulmão, kits, anticorpo anti-pd-l1 e composições
|
|
WO2020023628A1
(en)
|
2018-07-24 |
2020-01-30 |
Hygia Pharmaceuticals, Llc |
Compounds, derivatives, and analogs for cancer
|
|
WO2020051099A1
(en)
|
2018-09-03 |
2020-03-12 |
Genentech, Inc. |
Carboxamide and sulfonamide derivatives useful as tead modulators
|
|
JP2022501332A
(ja)
|
2018-09-19 |
2022-01-06 |
ジェネンテック， インコーポレイテッド |
膀胱がんの治療方法および診断方法
|
|
KR102739487B1
(ko)
|
2018-09-21 |
2024-12-10 |
제넨테크, 인크. |
3중-음성 유방암에 대한 진단 방법
|
|
EP3860608A1
(en)
|
2018-10-04 |
2021-08-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Egfr inhibitors for treating keratodermas
|
|
US12404540B2
(en)
|
2018-10-17 |
2025-09-02 |
The University Of Queensland |
Epigenetic biomarker and uses therefor
|
|
MX2021004348A
(es)
|
2018-10-18 |
2021-05-28 |
Genentech Inc |
Procedimientos de diagnóstico y terapéuticos para el cáncer de riñón sarcomatoide.
|
|
JP7516029B2
(ja)
|
2018-11-16 |
2024-07-16 |
アムジエン・インコーポレーテツド |
Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
|
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
|
|
US11053226B2
(en)
|
2018-11-19 |
2021-07-06 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
|
EP3898615A1
(en)
|
2018-12-19 |
2021-10-27 |
Array Biopharma, Inc. |
7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
|
|
WO2020131627A1
(en)
|
2018-12-19 |
2020-06-25 |
Array Biopharma Inc. |
Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
|
|
WO2020132651A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Kif18a inhibitors
|
|
JP7676308B2
(ja)
|
2018-12-20 |
2025-05-14 |
アムジエン・インコーポレーテツド |
Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド
|
|
EP3898616B1
(en)
|
2018-12-20 |
2024-10-02 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
|
TWI844602B
(zh)
|
2018-12-20 |
2024-06-11 |
美商安進公司 |
Kif18a抑制劑
|
|
EP3921443A1
(en)
|
2019-02-08 |
2021-12-15 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for cancer
|
|
EP3931565A4
(en)
|
2019-02-27 |
2023-04-12 |
Epiaxis Therapeutics Pty Ltd |
METHODS AND MEANS OF EVALUATING T-CELL FUNCTION AND PREDICTING RESPONSE TO THERAPY
|
|
KR20210133237A
(ko)
|
2019-02-27 |
2021-11-05 |
제넨테크, 인크. |
항-tigit 및 항-cd20 또는 항-cd38 항체로 치료를 위한 투약
|
|
WO2020180768A1
(en)
|
2019-03-01 |
2020-09-10 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
|
CN113727758A
(zh)
|
2019-03-01 |
2021-11-30 |
锐新医药公司 |
双环杂环基化合物及其用途
|
|
TW202210480A
(zh)
|
2019-04-17 |
2022-03-16 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TW202212339A
(zh)
|
2019-04-17 |
2022-04-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
WO2020223233A1
(en)
|
2019-04-30 |
2020-11-05 |
Genentech, Inc. |
Prognostic and therapeutic methods for colorectal cancer
|
|
CN114269376A
(zh)
|
2019-05-03 |
2022-04-01 |
豪夫迈·罗氏有限公司 |
用抗pd-l1抗体治疗癌症的方法
|
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
|
NZ782284A
(en)
|
2019-05-21 |
2024-11-29 |
Amgen Inc |
Solid state forms
|
|
TWI879779B
(zh)
|
2019-06-28 |
2025-04-11 |
美商基利科學股份有限公司 |
類鐸受體調節劑化合物的製備方法
|
|
CN112300279A
(zh)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
针对抗cd73抗体和变体的方法和组合物
|
|
US12540129B2
(en)
|
2019-08-02 |
2026-02-03 |
Amgen Inc. |
KIF18A inhibitors
|
|
AU2020326627B2
(en)
|
2019-08-02 |
2026-01-29 |
Amgen Inc. |
KIF18A inhibitors
|
|
EP4007756B1
(en)
|
2019-08-02 |
2025-12-24 |
Amgen Inc. |
Kif18a inhibitors
|
|
WO2021026099A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
|
WO2021046159A1
(en)
|
2019-09-04 |
2021-03-11 |
Genentech, Inc. |
Cd8 binding agents and uses thereof
|
|
EP4048693A1
(en)
|
2019-09-27 |
2022-08-31 |
F. Hoffmann-La Roche AG |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
|
WO2021067875A1
(en)
|
2019-10-03 |
2021-04-08 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
|
EP4684786A3
(en)
|
2019-10-24 |
2026-04-08 |
Amgen Inc. |
Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
|
|
EP4051674A1
(en)
|
2019-10-29 |
2022-09-07 |
F. Hoffmann-La Roche AG |
Bifunctional compounds for the treatment of cancer
|
|
CN120699039A
(zh)
|
2019-11-04 |
2025-09-26 |
锐新医药公司 |
Ras抑制剂
|
|
MX2022005359A
(es)
|
2019-11-04 |
2022-06-02 |
Revolution Medicines Inc |
Inhibidores de ras.
|
|
WO2021091956A1
(en)
|
2019-11-04 |
2021-05-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
AU2020378330A1
(en)
|
2019-11-06 |
2022-05-12 |
F. Hoffmann-La Roche Ag |
Diagnostic and therapeutic methods for treatment of hematologic cancers
|
|
TW202128688A
(zh)
|
2019-11-08 |
2021-08-01 |
美商銳新醫藥公司 |
雙環雜芳基化合物及其用途
|
|
CN114728905B
(zh)
|
2019-11-13 |
2025-08-01 |
基因泰克公司 |
治疗性化合物及使用方法
|
|
WO2021097207A1
(en)
|
2019-11-14 |
2021-05-20 |
Amgen Inc. |
Improved synthesis of kras g12c inhibitor compound
|
|
JP2023501528A
(ja)
|
2019-11-14 |
2023-01-18 |
アムジエン・インコーポレーテツド |
Ｋｒａｓ ｇ１２ｃ阻害剤化合物の改善された合成
|
|
WO2021097256A1
(en)
|
2019-11-14 |
2021-05-20 |
Cohbar, Inc. |
Cxcr4 antagonist peptides
|
|
EP4065231A1
(en)
|
2019-11-27 |
2022-10-05 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
|
WO2021119505A1
(en)
|
2019-12-13 |
2021-06-17 |
Genentech, Inc. |
Anti-ly6g6d antibodies and methods of use
|
|
EP4076667A1
(en)
|
2019-12-20 |
2022-10-26 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
CN114929279A
(zh)
|
2020-01-07 |
2022-08-19 |
锐新医药公司 |
Shp2抑制剂给药和治疗癌症的方法
|
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
|
CN115315256A
(zh)
|
2020-01-27 |
2022-11-08 |
基因泰克公司 |
用抗tigit拮抗剂抗体治疗癌症的方法
|
|
WO2021177980A1
(en)
|
2020-03-06 |
2021-09-10 |
Genentech, Inc. |
Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
|
|
WO2021233534A1
(en)
|
2020-05-20 |
2021-11-25 |
Pvac Medical Technologies Ltd |
Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
|
|
WO2021185844A1
(en)
|
2020-03-16 |
2021-09-23 |
Pvac Medical Technologies Ltd |
Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
|
|
EP4127724A1
(en)
|
2020-04-03 |
2023-02-08 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
EP4136228A4
(en)
|
2020-04-15 |
2024-09-11 |
California Institute of Technology |
THERMAL REGULATION OF T-CELL IMMUNOTHERAPY BY MOLECULAR AND PHYSICAL ACTUATION
|
|
EP4143345A1
(en)
|
2020-04-28 |
2023-03-08 |
Genentech, Inc. |
Methods and compositions for non-small cell lung cancer immunotherapy
|
|
MX2022015877A
(es)
|
2020-06-16 |
2023-01-24 |
Genentech Inc |
Metodos y composiciones para tratar cancer de mama triple negativo.
|
|
IL299131A
(en)
|
2020-06-18 |
2023-02-01 |
Revolution Medicines Inc |
Methods for delaying, preventing and treating acquired resistance to RAS inhibitors
|
|
CN115916348A
(zh)
|
2020-06-18 |
2023-04-04 |
基因泰克公司 |
使用抗tigit抗体和pd-1轴结合拮抗剂的治疗
|
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
|
EP4189121A1
(en)
|
2020-08-03 |
2023-06-07 |
Genentech, Inc. |
Diagnostic and therapeutic methods for lymphoma
|
|
EP4192509A1
(en)
|
2020-08-05 |
2023-06-14 |
Ellipses Pharma Ltd |
Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
|
|
EP4196612A1
(en)
|
2020-08-12 |
2023-06-21 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
WO2022036285A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase
|
|
WO2022036265A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Chimeric tim receptors and uses thereof
|
|
WO2022036287A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Anti-cd72 chimeric receptors and uses thereof
|
|
US11999964B2
(en)
|
2020-08-28 |
2024-06-04 |
California Institute Of Technology |
Synthetic mammalian signaling circuits for robust cell population control
|
|
MX2023002248A
(es)
|
2020-09-03 |
2023-05-16 |
Revolution Medicines Inc |
Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
|
|
MX2023003060A
(es)
|
2020-09-15 |
2023-04-05 |
Revolution Medicines Inc |
Derivados indolicos como inhibidores de ras en el tratamiento del cancer.
|
|
AU2021347232A1
(en)
|
2020-09-23 |
2023-04-27 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
KR20230082632A
(ko)
|
2020-10-05 |
2023-06-08 |
제넨테크, 인크. |
항-fcrh5/항-cd3 이중특이성 항체를 사용한 치료를 위한 투약
|
|
TW202237638A
(zh)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
|
|
WO2022133345A1
(en)
|
2020-12-18 |
2022-06-23 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
US20240051956A1
(en)
|
2020-12-22 |
2024-02-15 |
Qilu Regor Therapeutics Inc. |
Sos1 inhibitors and uses thereof
|
|
WO2022140456A1
(en)
|
2020-12-22 |
2022-06-30 |
Mekanistic Therapeutics Llc |
Substituted aminobenzyl heteroaryl compounds as egfr and/or pi3k inhibitors
|
|
JP7821808B2
(ja)
|
2021-02-12 |
2026-02-27 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療のための二環式テトラヒドロアゼピン誘導体
|
|
AU2022227021A1
(en)
|
2021-02-26 |
2023-09-21 |
Kelonia Therapeutics, Inc. |
Lymphocyte targeted lentiviral vectors
|
|
CA3217393A1
(en)
|
2021-05-05 |
2022-11-10 |
Elena S. Koltun |
Ras inhibitors
|
|
AU2022268962A1
(en)
|
2021-05-05 |
2023-12-14 |
Revolution Medicines, Inc. |
Ras inhibitors for the treatment of cancer
|
|
WO2022235866A1
(en)
|
2021-05-05 |
2022-11-10 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
|
CA3221390A1
(en)
|
2021-05-25 |
2022-12-01 |
Erasca, Inc. |
Sulfur-containing heteroaromatic tricyclic kras inhibitors
|
|
US20240293558A1
(en)
|
2021-06-16 |
2024-09-05 |
Erasca, Inc. |
Kras inhibitor conjugates
|
|
JP2024529474A
(ja)
|
2021-07-28 |
2024-08-06 |
セロ・セラピューティクス・インコーポレイテッド |
キメラＴｉｍ４受容体およびその使用
|
|
WO2023018699A1
(en)
|
2021-08-10 |
2023-02-16 |
Erasca, Inc. |
Selective kras inhibitors
|
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
|
EP4436957A1
(en)
|
2021-11-24 |
2024-10-02 |
Genentech, Inc. |
Therapeutic indazole compounds and methods of use in the treatment of cancer
|
|
TW202340212A
(zh)
|
2021-11-24 |
2023-10-16 |
美商建南德克公司 |
治療性化合物及其使用方法
|
|
TW202340214A
(zh)
|
2021-12-17 |
2023-10-16 |
美商健臻公司 |
做為shp2抑制劑之吡唑并吡𠯤化合物
|
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
WO2023172858A1
(en)
|
2022-03-07 |
2023-09-14 |
Amgen Inc. |
A process for preparing 4-methyl-2-propan-2-yl-pyridine-3-carbonitrile
|
|
CN119136806A
(zh)
|
2022-03-08 |
2024-12-13 |
锐新医药公司 |
用于治疗免疫难治性肺癌的方法
|
|
IL315770A
(en)
|
2022-04-01 |
2024-11-01 |
Genentech Inc |
Dosage for treatment with bispecific anti-FCRH5/anti-CD3 antibodies
|
|
CN119317641A
(zh)
|
2022-05-11 |
2025-01-14 |
基因泰克公司 |
针对用抗fcrh5/抗cd3双特异性抗体进行治疗的给药
|
|
EP4537107A2
(en)
|
2022-06-07 |
2025-04-16 |
Genentech, Inc. |
Method for determining the efficacy of a lung cancer treatment comprising an anti-pd-l1 antagonist and an anti-tigit antagonist antibody
|
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
JP2025523020A
(ja)
|
2022-07-13 |
2025-07-17 |
ジェネンテック， インコーポレイテッド |
抗ＦｃＲＨ５／抗ＣＤ３二重特異性抗体による処置のための投与
|
|
CA3261510A1
(en)
|
2022-07-19 |
2024-01-25 |
F. Hoffmann-La Roche Ag |
DOSAGE FOR TREATMENT WITH BISOPECIFIC ANTI-FCRH5/ANTI-CD3 ANTIBODIES
|
|
US20260041767A1
(en)
|
2022-08-02 |
2026-02-12 |
National University Corporation Hokkaido University |
Methods of improving cellular therapy with organelle complexes
|
|
TW202417001A
(zh)
|
2022-08-11 |
2024-05-01 |
瑞士商赫孚孟拉羅股份公司 |
雙環四氫吖呯衍生物
|
|
CR20250043A
(es)
|
2022-08-11 |
2025-03-25 |
Hoffmann La Roche |
Derivados bicíclicos de tetrahidrotiazepina
|
|
WO2024033388A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
|
WO2024033457A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
|
AU2023358792A1
(en)
|
2022-10-14 |
2025-04-17 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|
|
JP2025538859A
(ja)
|
2022-10-21 |
2025-12-02 |
公益財団法人川崎市産業振興財団 |
非吸着性またはスーパーステルス小胞
|
|
WO2024091991A1
(en)
|
2022-10-25 |
2024-05-02 |
Genentech, Inc. |
Therapeutic and diagnostic methods for multiple myeloma
|
|
TW202434206A
(zh)
|
2023-02-17 |
2024-09-01 |
美商伊瑞斯卡公司 |
Ｋｒａｓ抑制劑
|
|
EP4687905A1
(en)
|
2023-03-30 |
2026-02-11 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
|
CN121263418A
(zh)
|
2023-04-07 |
2026-01-02 |
锐新医药公司 |
大环ras抑制剂
|
|
KR20260005904A
(ko)
|
2023-04-07 |
2026-01-12 |
레볼루션 메디슨즈, 인크. |
매크로사이클릭 ras 억제제
|
|
AU2024252105A1
(en)
|
2023-04-14 |
2025-10-16 |
Revolution Medicines, Inc. |
Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
|
|
KR20250172857A
(ko)
|
2023-04-14 |
2025-12-09 |
레볼루션 메디슨즈, 인크. |
Ras 억제제의 결정형
|
|
AU2024265078A1
(en)
|
2023-05-04 |
2025-12-11 |
Revolution Medicines, Inc. |
Combination therapy for a ras related disease or disorder
|
|
WO2024233341A1
(en)
|
2023-05-05 |
2024-11-14 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
CN121285742A
(zh)
|
2023-06-08 |
2026-01-06 |
基因泰克公司 |
用于淋巴瘤的诊断和治疗方法的巨噬细胞特征
|
|
WO2025024257A1
(en)
|
2023-07-21 |
2025-01-30 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
IL326136A
(en)
|
2023-08-07 |
2026-03-01 |
Revolution Medicines Inc |
RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
|
|
WO2025049277A1
(en)
|
2023-08-25 |
2025-03-06 |
Genentech, Inc. |
Methods and compositions for treating non-small cell lung cancer comprising an anti-tigit antagonist antibody and a pd-1 axis binding antagonist
|
|
US20250154171A1
(en)
|
2023-10-12 |
2025-05-15 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
TW202542151A
(zh)
|
2023-12-22 |
2025-11-01 |
美商銳格醫藥有限公司 |
Ｓｏｓ１抑制劑及其用途
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
US20250375445A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
CN118834200A
(zh)
*
|
2024-06-27 |
2024-10-25 |
辽宁大学 |
含酰胺结构的4-苯胺基喹唑啉类化合物及其应用
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026030476A1
(en)
|
2024-07-30 |
2026-02-05 |
Genentech, Inc. |
Precision medicine for optimal dosage of combined therapies systems and methods of use thereof
|
|
WO2026030464A1
(en)
|
2024-07-30 |
2026-02-05 |
Genentech, Inc. |
Dosage regimen for reducing cytokine release syndrome (crs) with anti-fcrh5/anti-cd3 bispecific antibodies in multiple myeloma therapy
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|